scholarly article | Q13442814 |
P50 | author | Masataka Tsuge | Q58842302 |
C Nelson Hayes | Q87781870 | ||
Kazuaki Chayama | Q87781872 | ||
Tomokazu Kawaoka | Q88437730 | ||
Hiroshi Aikata | Q89534368 | ||
Michio Imamura | Q90938539 | ||
Takashi Nakahara | Q92376870 | ||
Yoshiiku Kawakami | Q114882129 | ||
Hidenori Ochi | Q114899201 | ||
Nobuhiko Hiraga | Q114921454 | ||
Atsushi Ono | Q118189231 | ||
Hiromi Kan | Q118189235 | ||
Grace Naswa Makokha | Q55277932 | ||
Daiki Miki | Q55965588 | ||
P2093 | author name string | Keiichi Masaki | |
Eisuke Miyaki | |||
Hiromi Abe-Chayama | |||
Takuro Uchida | |||
Yizhou Zhang | |||
Makokha Grace Naswa | |||
P2860 | cites work | Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis | Q70004003 |
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up | Q80229621 | ||
The new front-line in hepatitis B/D research: identification and blocking of a functional receptor | Q86077014 | ||
Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin | Q93711355 | ||
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus | Q21128797 | ||
Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). | Q33998195 | ||
Management of chronic hepatitis B. | Q35068048 | ||
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas | Q35598151 | ||
Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen | Q36213588 | ||
A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees | Q37410079 | ||
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. | Q37418293 | ||
Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. | Q38310253 | ||
Near completely humanized liver in mice shows human-type metabolic responses to drugs | Q38781911 | ||
Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children | Q40132547 | ||
Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus | Q40357899 | ||
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome | Q40679075 | ||
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. | Q43208914 | ||
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. | Q43645392 | ||
Hepatitis B immune serum globulin in prevention of nonparenterally transmitted hepatitis B. | Q44066713 | ||
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 | ||
Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection | Q45121099 | ||
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. | Q45396940 | ||
Genetic restriction of immune responsiveness to synthetic peptides corresponding to sequences in the pre-S region of the hepatitis B virus (HBV) envelope gene | Q45827803 | ||
Modulation of the immunological response to hepatitis B virus by antibodies | Q45831241 | ||
The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma | Q45842104 | ||
Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee | Q45848619 | ||
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b | Q46514441 | ||
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. | Q54373860 | ||
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 | ||
Hepatitis B virus and hepatocellular carcinoma | Q58021990 | ||
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response | Q58097652 | ||
P433 | issue | 11 | |
P921 | main subject | chronic hepatitis B | Q55779876 |
P304 | page(s) | 1073-1080 | |
P577 | publication date | 2016-03-04 | |
P1433 | published in | Journal of Gastroenterology | Q15764399 |
P1476 | title | Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection | |
P478 | volume | 51 |
Q47557548 | A mouse model with age-dependent immune response and immune-tolerance for HBV infection |
Q41671765 | A potent human neutralizing antibody Fc-dependently reduces established HBV infections |
Q39067120 | Antibody-dependent and antibody-independent uptake of HBsAg across human leucocyte subsets is similar between individuals with chronic hepatitis B virus infection and healthy donors |
Q90681199 | Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection |
Q39101021 | Research progress of therapeutic vaccines for treating chronic hepatitis B. |
Q90681211 | Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response |
Search more.